


PHARMACEUTICAL 2023

PLIANT THERAPEUTICS INC. Rank 85 of 446









RealRate

PHARMACEUTICAL 2023

PLIANT THERAPEUTICS INC. Rank 85 of 446



The relative strengths and weaknesses of PLIANT THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PLIANT THERAPEUTICS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 93% points. The greatest weakness of PLIANT THERAPEUTICS INC. is the variable Other Revenues, reducing the Economic Capital Ratio by 13% points.

The company's Economic Capital Ratio, given in the ranking table, is 214%, being 171% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	340,311
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	23,913
Liabilities, Non-Current	3,429
Other Assets	5,816
Other Compr. Net Income	-1,757
Other Expenses	0
Other Liabilities	9,929
Other Net Income	3,879
Other Revenues	9,685
Property and Equipment	4,486
Research and Development	96,936
Selling, General and Administrative Expense	39,949

Output Variable	Value in 1000 USD
Assets	350,613
Liabilities	37,271
Expenses	136,885
Revenues	9,685
Stockholders Equity	313,342
Net Income	-123,321
Comprehensive Net Income	-124,200
Economic Capital Ratio	214%

